Groningen, the Netherlands, 12 November 2010 -- Dutch biotechnology company Mucosis B.V. announced today that Dr Barry Buckland was elected to its Supervisory Board. Dr Buckland brings extensive experience in vaccine design and development.
From 1996 to 2009, Dr Buckland was Vice President, BioProcess R&D at Merck & Co,
Inc. He built the unit and was responsible for process development for 14 new
commercial products, including 10 new vaccines. More recently Dr Buckland has been a
consultant to Hilleman Laboratories, the vaccine venture established between Merck and
The Wellcome Trust. Dr Buckland received many professional and academic honors,
including the 2008 Marvin Johnson Award from the American Chemical Society for
lifetime contribution to biotechnology. He has authored 77 scientific papers.
“I am delighted to have this opportunity to contribute to the success of Mucosis”
commented Dr Buckland. “The Company’s mucosal immunity platform will have many
applications in developing superior vaccines”.
John Lambert, Chairman of Mucosis added: “Barry’s insight and experience stem from
being involved in the design, development and commercialization of many of today’s
blockbuster vaccines. He will be invaluable to Mucosis”.
For further information please contact:
+31 (6) 55320948